. home.aspx

NEWS

home.aspx
   


Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer

July 26, 2016 /
SHARESHARESHARE

RARITAN, NJ – July 26, 2016 -- Janssen Biotech, Inc. announced today it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC). The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO® (nivolumab), in NSCLC patients.